4D MOLECULAR THERAPEUTICS IN's ticker is FDMT and the CUSIP is 35104E100. A total of 81 filers reported holding 4D MOLECULAR THERAPEUTICS IN in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $696,318 | -33.7% | 54,699 | -5.9% | 0.00% | 0.0% |
| Q2 2023 | $1,050,897 | -45.3% | 58,157 | -47.9% | 0.00% | 0.0% |
| Q1 2023 | $1,919,745 | +234.8% | 111,678 | +332.6% | 0.00% | – |
| Q4 2022 | $573,373 | +616.7% | 25,816 | +160.9% | 0.00% | – |
| Q3 2022 | $80,000 | -5.9% | 9,894 | -19.1% | 0.00% | – |
| Q2 2022 | $85,000 | -80.3% | 12,237 | -57.2% | 0.00% | – |
| Q1 2022 | $432,000 | -76.3% | 28,595 | -65.6% | 0.00% | -100.0% |
| Q4 2021 | $1,825,000 | +2301.3% | 83,172 | +2867.2% | 0.00% | – |
| Q3 2021 | $76,000 | +100.0% | 2,803 | +76.8% | 0.00% | – |
| Q2 2021 | $38,000 | -35.6% | 1,585 | +15.9% | 0.00% | – |
| Q1 2021 | $59,000 | – | 1,368 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BVF INC/IL | 4,007,413 | $68,887,429 | 2.52% |
| Opaleye Management Inc. | 314,000 | $5,397,660 | 1.62% |
| Deep Track Capital, LP | 2,278,107 | $39,160,659 | 1.61% |
| Casdin Capital, LLC | 1,070,000 | $18,393,300 | 1.52% |
| Eagle Health Investments LP | 437,911 | $7,527,690 | 1.46% |
| ACUTA CAPITAL PARTNERS, LLC | 104,753 | $1,800,704 | 1.33% |
| Octagon Capital Advisors LP | 499,996 | $8,594,931 | 1.24% |
| Soleus Capital Management, L.P. | 469,400 | $8,068,986 | 0.84% |
| Novo Holdings A/S | 700,000 | $12,033,000 | 0.79% |
| VIKING GLOBAL INVESTORS LP | 3,937,914 | $67,692,742 | 0.32% |